Advanced Pharma Consulting Pty Ltd

Status: Deregistered
Australian Company Number: 161952414
Australian Business Number: 11161952414
Date deregistered: 26th April 2016
Type: Australian proprietary company
Class: Limited by Shares
Subclass: Proprietary other
last updated

Description

The following company has been deregistered. Advanced Pharma Consulting Pty Ltd was a limited by shares, Australian proprietary company. The corporation was issued an ACN - 161952414 and an ABN - 11161952414. On 2015-10-07, the company established a HQ in NSW, post code 2041. Previous headquarters addresses include NSW 2041 (from 2014-09-18 to 2015-10-07), NSW 2041 (from 2013-01-16 to 2014-09-18). Advanced Pharma Consulting Pty Ltd was de-registered on 2016-04-26. The above mentioned data comes from the ABN database it was last updated on 2017-08-18.

Advertisements

Details for ABN 11161952414

Type: Australian Private Company

ABN Status

Status From To
Cancelled 18th August 2017 current
Active 16th January 2013 18th August 2017

Main Name

Name From To
Advanced Pharma Consulting Pty Ltd 16th January 2013 current

Main Location

Location From To
NSW 2041 7th October 2015 current
NSW 2041 18th September 2014 7th October 2015
NSW 2041 16th January 2013 18th September 2014

Advertisements

Find company

NSW 2041 Location

2018 © aubiz.net - ABN Lookup, ACN, ABR, ABN Search. All rights reserved.
Contact us: info@aubiz.net
Terms of Use and Privacy Policy

Contains public sector information licensed under the Creative Commons Attribution 3.0 Australia licence. Material on this website was obtained from publicly-accessible databases and is attributed to ©Commonwealth of Australia 2018 (http://data.gov.au, http://acnc.gov.au/ and http://abr.business.gov.au/), ©Intellectual Property Government Open Data 2018, ©ASIC - Company Register. While we try to make the information as precise and up-to-date as possible, we are aware the datasets are not always error-free. Aubiz.net will not take responsibility for any errors in the databases. The material provided should be treated as a starting point of more in-depth research, not as fact.